Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions

M. Javle; R. K. Kelley; S. Roychowdhury; K. H. Weiss; G. K. Abou-Alfa; T. Macarulla; S. Sadeghi; D. Waldschmidt; A. X. Zhu; L. Goyal; M. Borad; W. P. Yong; I. Borbath; A. El-Khoueiry; P. Philip; S. Moran; Y. Ye; M. Ising; N. Lewis; T. Bekaii-Saab

doi:10.1093/annonc/mdy424.030

Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions

M. Javle, R. K. Kelley, S. Roychowdhury, K. H. Weiss, G. K. Abou-Alfa, T. Macarulla, S. Sadeghi, D. Waldschmidt, A. X. Zhu, L. Goyal, M. Borad, W. P. Yong, I. Borbath, A. El-Khoueiry, P. Philip, S. Moran, Y. Ye, M. Ising, N. Lewis, T. Bekaii-Saab

Hematology/Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii720
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy424.030
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy424.030

Cite this

Javle, M., Kelley, R. K., Roychowdhury, S., Weiss, K. H., Abou-Alfa, G. K., Macarulla, T., Sadeghi, S., Waldschmidt, D., Zhu, A. X., Goyal, L., Borad, M., Yong, W. P., Borbath, I., El-Khoueiry, A., Philip, P., Moran, S., Ye, Y., Ising, M., Lewis, N., & Bekaii-Saab, T. (2018). Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii720. https://doi.org/10.1093/annonc/mdy424.030

Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. / Javle, M.; Kelley, R. K.; Roychowdhury, S. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii720.

Research output: Contribution to journal › Article › peer-review

Javle, M, Kelley, RK, Roychowdhury, S, Weiss, KH, Abou-Alfa, GK, Macarulla, T, Sadeghi, S, Waldschmidt, D, Zhu, AX, Goyal, L, Borad, M, Yong, WP, Borbath, I, El-Khoueiry, A, Philip, P, Moran, S, Ye, Y, Ising, M, Lewis, N & Bekaii-Saab, T 2018, 'Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii720. https://doi.org/10.1093/annonc/mdy424.030

Javle M, Kelley RK, Roychowdhury S, Weiss KH, Abou-Alfa GK, Macarulla T et al. Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii720. doi: 10.1093/annonc/mdy424.030

@article{32c8eb21bc334a089ee437694d166351,

title = "Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions",

author = "M. Javle and Kelley, {R. K.} and S. Roychowdhury and Weiss, {K. H.} and Abou-Alfa, {G. K.} and T. Macarulla and S. Sadeghi and D. Waldschmidt and Zhu, {A. X.} and L. Goyal and M. Borad and Yong, {W. P.} and I. Borbath and A. El-Khoueiry and P. Philip and S. Moran and Y. Ye and M. Ising and N. Lewis and T. Bekaii-Saab",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy424.030",

language = "English (US)",

volume = "29",

pages = "viii720",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions

AU - Javle, M.

AU - Kelley, R. K.

AU - Roychowdhury, S.

AU - Weiss, K. H.

AU - Abou-Alfa, G. K.

AU - Macarulla, T.

AU - Sadeghi, S.

AU - Waldschmidt, D.

AU - Zhu, A. X.

AU - Goyal, L.

AU - Borad, M.

AU - Yong, W. P.

AU - Borbath, I.

AU - El-Khoueiry, A.

AU - Philip, P.

AU - Moran, S.

AU - Ye, Y.

AU - Ising, M.

AU - Lewis, N.

AU - Bekaii-Saab, T.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081530902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081530902&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy424.030

DO - 10.1093/annonc/mdy424.030

M3 - Article

C2 - 32137992

SN - 0923-7534

VL - 29

SP - viii720

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this